U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C17H23NO3
Molecular Weight 289.3701
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ATROPINE

SMILES

CN1[C@@]2([H])CC[C@]1([H])C[C@@]([H])(C2)OC(=O)C([H])(CO)c3ccccc3

InChI

InChIKey=RKUNBYITZUJHSG-SPUOUPEWSA-N
InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15+,16?

HIDE SMILES / InChI

Molecular Formula C17H23NO3
Molecular Weight 289.3701
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 2 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68001285 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206289s000lbl.pdf

Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily than with responses to injected (exogenous) choline esters. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors.

Originator

Curator's Comment:: Atropine was first obtained from the deadly nightshade (Atropa belladonna) by M. Brandes in 1819.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

9.9455042E11
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

9.9455042E11
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

9.9455042E11
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

9.9455042E11
Primary
Atropine sulfate

Approved Use

Atropine sulfate is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.

Launch Date

9.9455042E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
860 pg/mL
0.4 μg single, ocular
dose: 0.4 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
11.7 ng/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.6 ng/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43245 pg × min/mL
0.4 μg single, ocular
dose: 0.4 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
47.6 ng × h/mL
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 h
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82%
1.67 mg single, intramuscular
dose: 1.67 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ATROPINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Kounis syndrome, Chest discomfort...
AEs leading to
discontinuation/dose reduction:
Kounis syndrome (1 patient)
Chest discomfort (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Photophobia, Reading disorder...
Other AEs:
Photophobia (70%)
Reading disorder (25.9%)
Headache (21.7%)
Hot flushes (3.3%)
Conjunctivitis (1.7%)
Blepharitis (1.7%)
Sources:
1 mg single, sublingual
Overdose
Dose: 1 mg
Route: sublingual
Route: single
Dose: 1 mg
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Other AEs: Adverse event...
Other AEs:
Adverse event (severe)
Sources:
AEs

AEs

AESignificanceDosePopulation
Chest discomfort 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Kounis syndrome 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
0.1 mg/kg single, intravenous
Dose: 0.1 mg/kg
Route: intravenous
Route: single
Dose: 0.1 mg/kg
Sources:
unhealthy, 10 years
n = 1
Health Status: unhealthy
Age Group: 10 years
Sex: M
Population Size: 1
Sources:
Blepharitis 1.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Conjunctivitis 1.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Headache 21.7%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Reading disorder 25.9%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Hot flushes 3.3%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Photophobia 70%
0.5 % 1 times / day multiple, ophthalmic
Highest studied dose
Dose: 0.5 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 0.5 %, 1 times / day
Sources:
unhealthy, 10.3 years (range: 2.7–16.8 years)
n = 77
Health Status: unhealthy
Condition: progressive myopia
Age Group: 10.3 years (range: 2.7–16.8 years)
Sex: M+F
Population Size: 77
Sources:
Adverse event severe
1 mg single, sublingual
Overdose
Dose: 1 mg
Route: sublingual
Route: single
Dose: 1 mg
Sources:
unhealthy
n = 1
Health Status: unhealthy
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 1.2 uM]
yes [IC50 39 uM]
yes [IC50 466 uM]
PubMed

PubMed

TitleDatePubMed
Selective blocking effects of tropisetron and atropine on recombinant glycine receptors.
1999 Aug
Attenuation of focal adhesion kinase signaling following depletion of agonist-sensitive pools of phosphatidylinositol 4,5-bisphosphate.
1999 Nov
Focal microinjection of carbachol into the periaqueductal gray induces seizures in the forebrain of the rat.
2000 Dec
Acute cardiac rupture during dobutamine-atropine echocardiography stress test.
2000 Feb
Influence of nitric oxide donors and of the alpha(2)-agonist UK-14,304 on acetylcholine release in the pig gastric fundus.
2001
Endothelin receptors in human and guinea-pig gallbladder muscle.
2001 Apr 20
Localisation and neural control of the release of calcitonin gene-related peptide (CGRP) from the isolated perfused porcine ileum.
2001 Apr 20
Accelerated dobutamine stress testing: safety and feasibility in patients with known or suspected coronary artery disease.
2001 Feb
On the mechanisms of cholinergic control of the sinoatrial node discharge.
2001 Feb
Sublingual hyoscyamine sulfate in combination with ketorolac tromethamine for ureteral colic: a randomized, double-blind, controlled trial.
2001 Feb
Cardiac sympathetic overactivity and decreased baroreflex sensitivity in L-NAME hypertensive rats.
2001 Feb
Muscarinic receptor subtypes and calcium signaling in Fischer rat thyroid cells.
2001 Feb 1
Characterisation of the prejunctional inhibitory muscarinic receptor on cholinergic nerves in the rat urinary bladder.
2001 Feb 16
Stimulation of M3 muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway.
2001 Feb 23
Increase of peak expiratory flow by atropine is dependent on circadian rhythm.
2001 Jan
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade.
2001 Jan
Tachykinins contribute to nerve-mediated contractions in the human esophagus.
2001 Jan
Influence of patient posture on oxygen saturation during fibre-optic bronchoscopy.
2001 Jan
Hypotensive infarction of the spinal cord in a rhesus macaque (Macaca mulatta).
2001 Jan
Spectral analysis of circadian rhythms in heart rate variability of dogs.
2001 Jan
Effects of VIP and NO on the motor activity of vascularly perfused rat proximal colon.
2001 Jan
Neural mechanisms underlying migrating motor complex formation in mouse isolated colon.
2001 Jan
Evidence for cocaine and methylecgonidine stimulation of M(2) muscarinic receptors in cultured human embryonic lung cells.
2001 Jan
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.
2001 Jan
Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men.
2001 Jan
Reversal of Haemorrhagic Shock in Rats by Tetrahydroaminoacridine.
2001 Jan
Non-synaptic transformation of gustatory receptor potential by stimulation of the parasympathetic fiber of the frog glossopharyngeal nerve.
2001 Jan
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.
2001 Jan 1
Effects of preemptive atropine administration on incidence of medetomidine-induced bradycardia in dogs.
2001 Jan 1
Post-ictal analgesia: involvement of opioid, serotoninergic and cholinergic mechanisms.
2001 Jan 12
Changes in sensitivity of cholinoceptors and adrenoceptors during transhemispheric cortical reorganisation in rat SmI.
2001 Jan 12
Determination of scopolamine in human serum and microdialysis samples by liquid chromatography-tandem mass spectrometry.
2001 Jan 5
Activation of the parasympathetic nervous system is necessary for normal meal-induced insulin secretion in rhesus macaques.
2001 Mar
From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology.
2001 Mar
Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration.
2001 Mar
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.
2001 Mar
Respective roles of carbamylcholine and cyclic adenosine monophosphate in their synergistic regulation of cell cycle in thyroid primary cultures.
2001 Mar
Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects.
2001 Mar 16
5-Hydroxytryptamine and atropine inhibit nicotinic receptors in submucosal neurons.
2001 Mar 2
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms.
2001 May
Patents

Sample Use Guides

Atropine as an antisialagogue or for antivagal effects: initial single dose of 0.5 mg to 1 mg; as an antidote for organophosporous or muscarinic mushroom poisoning: initial single dose of 2 mg to 3 mg, repeated every 20­-30 minutes; for bradyasystolic cardiac arrest: 1 mg dose, repeated every 3-5 minutes if asystole persists; in patients with coronary artery disease: total dose should not exceed 0.03 mg/kg to 0.04 mg/kg.
Route of Administration: Other
In Vitro Use Guide
Atropine in doses -5.44 to -4.74 log mol/L totally inhibited the contraction induced by acetylcholine and carbachol in segmental pulmonary artery specimens taken from the patients undergoing thoracic surgery.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:11:21 UTC 2021
Edited
by admin
on Fri Jun 25 21:11:21 UTC 2021
Record UNII
7C0697DR9I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ATROPINE
EP   GREEN BOOK   HSDB   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
ATROPINE [USP]
Common Name English
ATROPINE [VANDF]
Common Name English
ATROPINE COMPONENT OF ATNAA
Common Name English
(+/-)-HYOSCYAMINE
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-(3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER
Common Name English
ATROPEN
Brand Name English
ATROPINE [WHO-DD]
Common Name English
HOMATROPINE HYDROBROMIDE IMPURITY D [EP]
Common Name English
ATROPINUM [HPUS]
Common Name English
ATROPINE COMPONENT OF DUODOTE
Common Name English
ATROPINE [ORANGE BOOK]
Common Name English
DUODOTE COMPONENT ATROPINE
Common Name English
ATROPINE ((+/-))
Common Name English
(3-ENDO)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL TROPATE
Common Name English
ATROPINE [MI]
Common Name English
ATROPINE, (+/-)-
Common Name English
ATNAA COMPONENT ATROPINE
Common Name English
ATROPINE [GREEN BOOK]
Common Name English
ATROPINE [EP MONOGRAPH]
Common Name English
ATROPINE [MART.]
Common Name English
ATROPINUM
HPUS  
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-8-METHYL-8-AZABICYCLO(3.2.1)OCT-3-YL ESTER, ENDO-(+/-)-
Common Name English
ATROPINE [EP]
Common Name English
1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (+/-)-TROPATE (ESTER)
Common Name English
ATROPINE [USP-RS]
Common Name English
DL-HYOSCYAMINE
Common Name English
Classification Tree Code System Code
NDF-RT N0000175370
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ATC A03CB03
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-VATC QA03BA01
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
LIVERTOX 74
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NDF-RT N0000175574
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ATC S01FA01
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NDF-RT N0000000125
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NCI_THESAURUS C29704
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ATC A03BA01
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-VATC QS01FA01
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
CFR 21 CFR 310.533
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 4.2
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
CFR 21 CFR 520.2520A
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-VATC QA03CB03
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 21.5
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 1.3
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
WHO-ATC S01BB01
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
NDF-RT N0000175700
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
Code System Code Type Description
USP_CATALOG
1044990
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY USP-RS
FDA UNII
7C0697DR9I
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
MESH
D001285
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
LACTMED
Atropine
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
CAS
51-55-8
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
WIKIPEDIA
ATROPINE
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
DRUG CENTRAL
260
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
NCI_THESAURUS
C28840
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
EVMPD
SUB00621MIG
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
ChEMBL
CHEMBL517712
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-104-8
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
DRUG BANK
DB00572
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
HSDB
2199
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
MERCK INDEX
M2136
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY Merck Index
RXCUI
1223
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY RxNorm
EPA CompTox
51-55-8
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
IUPHAR
320
Created by admin on Fri Jun 25 21:11:21 UTC 2021 , Edited by admin on Fri Jun 25 21:11:21 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
TARGET -> INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
ENANTIOMER -> RACEMATE
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
TARGET -> INHIBITOR
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC